Main Story
-
Hollywood's Preferred Luxury Destination in India: Phoenix Palladium Mumbai Hosts the Odyssey Premiere
Mumbai, Maharashtra, India Christopher Nolan, Matt Damon and Tom Holland brought Hollywood’s spotlight to Mumbai as they arrived at Phoenix Palladium for the India premiere of The Odyssey. As part of the film’s global promotional tour, the Academy Award-winning filmmaker chose Mumbai as the only Indian stop, with the premiere held at the state-of-the-art PVR…
Products
-
AccuSure AS9 Fully Automatic Digital Blood Pressure Monitor With Large Display
Original price was: ₹1,733.00.₹998.00Current price is: ₹998.00. -
AGEasy Max Group Fully Automatic One Touch Digital Blood Pressure Monitoring Device
Original price was: ₹1,405.00.₹949.00Current price is: ₹949.00. -
Automatic Digital Blood Pressure Monitor for Upper Arm, Large LCD Display
Original price was: ₹2,399.00.₹448.00Current price is: ₹448.00. -
Beurer German Engineering P0 13 Kid’s Pulse Oximeter I Fingertip Home Pulse Oximeter
Original price was: ₹2,745.00.₹1,538.00Current price is: ₹1,538.00. -
BPL Medical Technologies Bluetooth Enabled Arm Type Blood Pressure Monitor
Original price was: ₹6,563.00.₹5,199.00Current price is: ₹5,199.00.
Automobile
Tech
Entertainment
-
Hollywood's Preferred Luxury Destination in India: Phoenix Palladium Mumbai Hosts the Odyssey Premiere
Mumbai, Maharashtra, India Christopher Nolan, Matt Damon and Tom Holland brought Hollywood’s spotlight to Mumbai as they arrived at Phoenix Palladium for the India premiere of The Odyssey. As part of the film’s global promotional tour, the Academy Award-winning filmmaker chose Mumbai as the only Indian stop, with the premiere held at the state-of-the-art PVR…
Health
-

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
July 23, 2026 21:08 ET | Source: Scribe Therapeutics Inc. ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) — Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial…
-
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics. Pharmaceuticals Division sales were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales…
-

Rajasthan’s cash-plus scheme linked to healthier birth weights, finds study published in Nature Health
Programme combining cash transfers with counselling associated with 7.4 percentage-point drop in low birthweight among 90,000+ newborns from tribal communities in southern Rajasthan JAIPUR, India, July 22, 2026 /PRNewswire/ — A Rajasthan state government-run maternal nutrition programme that paired conditional cash transfers with nutrition counselling and community outreach was associated with meaningfully better birth outcomes for…
-
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
July 22, 2026 02:00 ET | Source: Healx Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310, an investigational oral combination…
-

Apollo Hospitals Brings Next-Generation Lysin Science to India’s Fight Against AMR – Collaborates with Precisio Biotix
HYDERABAD, India, July 21, 2026 /PRNewswire/ — Apollo Hospitals today announced a strategic collaboration with Precisio Biotix to accelerate the development and clinical adoption of lysin-based antimicrobials in India – marking a significant step forward in combating antimicrobial resistance (AMR). This partnership will focus on translational research, clinical validation, and potential deployment pathways for lysin-based therapies across…
-

Allogenetics Appoints Dr. Jeroen Rovers as Chief Medical Officer
Seasoned executive leader and physician-scientist brings deep immunology and transplant medicine experience Company strengthens executive team as it advances its lead ex vivo donor-organ therapy ALG-115 toward clinical entry ALG-115 is designed to transform the treatment of graft rejection in lung transplantation Hanover, Germany, July 21, 2026 – Allogenetics today announced the appointment of Jeroen Rovers,…
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.


























